Avalo Therapeutics's market cap is currently $74.92M. The company's EPS TTM is $-168.229; its P/E ratio is ―; Avalo Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 1.92M	$ 18.05M	$ 5.40M	$ 6.70M	$ 6.75M
Gross Profit	$ 640.00K	$ 14.62M	$ 3.91M	$ 6.40M	$ -4.88M
Operating Income	$ -23.44M	$ -37.44M	$ -82.13M	$ -26.95M	$ -17.39M
EBITDA	$ -27.95M	$ -37.29M	$ -80.50M	$ -45.45M	$ -17.36M
Net Income	$ -31.54M	$ -41.66M	$ -84.35M	$ -64.38M	$ -16.27M
Balance Sheet
Cash & Short-Term Investments	$ 7.42M	$ 13.17M	$ 54.59M	$ 18.92M	$ 11.24M
Total Assets	$ 20.99M	$ 33.37M	$ 80.21M	$ 43.76M	$ 36.11M
Total Debt	$ 537.00K	$ 19.42M	$ 32.83M	$ 426.35K	$ 1.27M
Net Debt	$ -6.88M	$ 6.24M	$ -21.75M	$ -18.49M	$ -2.34M
Total Liabilities	$ 13.69M	$ 44.28M	$ 57.13M	$ 19.19M	$ 15.11M
Stockholders' Equity	$ 7.30M	$ -10.91M	$ 23.08M	$ 24.56M	$ 21.00M
Cash Flow
Free Cash Flow	$ -30.84M	$ -26.85M	$ -71.00M	$ -40.60M	$ -19.40M
Operating Cash Flow	$ -30.68M	$ -26.75M	$ -70.89M	$ -40.54M	$ -19.13M
Investing Cash Flow	$ -133.00K	$ -95.00K	$ -113.00K	$ 11.13M	$ -443.00K
Financing Cash Flow	$ 25.04M	$ -14.70M	$ 106.76M	$ 44.78M	$ 12.56M

Currency in USD

Avalo Therapeutics Earnings and Revenue History

Income Statement >

Avalo Therapeutics Debt to Assets

Balance Sheet >

Avalo Therapeutics Cash Flow

Cash Flow >

Avalo Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing